DFDavid Falck

David Falck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David Falck has a total of 289 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mannose receptor contributes to preferential oligomannosidic glycoform clearance in a murine pharmacokinetics model

    by David Falck, Steinar Gijze, Anna M. Wasynczuk, Sebastian Malik, Aline Tridon, Martin Lechmann, Manfred Wuhrer, Dietmar Reusch

    The pharmacokinetic profile of therapeutic antibodies, which affects the dosing frequency, efficacy, and cost of the products, is influenced by several molecular features, including N- glycosylation. While the accelerated clearance of antibodies carrying non-complex type glycans is well established, the mechanism behind this phenomenon is poorly understood. Though there have been indirect indications before, we provide the first direct evidence for the involvement of the mannose receptor in the clearance of therapeutic antibodies. Wild-type (WT) mice showed accelerated clearance of an oligomannose enriched antibody, and this effect was reduced in mannose receptor (MRC1) knockout (KO) mice. Subsequent glycoform-resolved analysis by mass spectrometry showed in WT an accelerated clearance of oligomannosidic compared to complex glycoforms. This accelerated clearance was also observed in MRC1 KO mice, but to a lesser extent. Interestingly, the glycoform distribution of total circulating mouse antibodies, which do not contain oligomannosidic glycoforms, was not affected by MRC1 KO. Hence, we show that the mannose receptor is involved in, but not exclusively responsible for, preferential clearance of oligomannosidic glycoforms of antibodies. This points toward a role for additional, glycan-targeting receptors for therapeutic antibody clearance. In addition, we observed a preferential clearance of complex afucosylated glycoforms, unique to the mouse model, which was MRC1-independent.

  • Open Access

    Site-specific profiling of structure and function of Igµ B cell receptor glycans

    by M. D. Holborough-Kerkvliet, L. Hafkenscheid, S. Kroos, R. Biersteker, R. van de Wetering, O. Singh, E. Fadda, R. T. N. Tjokrodirijo, P. A. van Veelen, M. Wuhrer, et al.

    Although N-linked glycans play pivotal roles in the regulation of antibody effector functions, little is known about the composition and functional impact of glycans attached to human B cell receptors (BCR). Here, we describe the site-specific glycosylation profiles of all 4 N-linked glycosylation sites of human Igµ BCRs from primary naive and memory B cells. Our data indicate that the Igµ BCR glycans do not undergo structural changes during transition from naive to memory cells, as healthy donor-derived BCRs from both B cell subtypes carry similar glycans. Conversely, serum IgM antibodies display distinct glycosylation features to Igµ BCRs, which are in part explained by the different molecular form of Igµ BCRs and IgM antibodies. Moreover, using B cell lines expressing defined BCRs, we show that, although the absence of the Igµ BCR N209 glycans reduces antigen binding, the individual glycosylation sites are nonessential for cell surface expression and BCR internalization following BCR triggering. Collectively, we show high conservation of Igµ BCR glycosylation across B cell subsets and limited contribution to BCR expression and function, suggesting BCR glycans may have evolved to support IgM antibody functions.


  • Open Access

    Fc Profiling of Polyclonal IgG, IgA and IgM by Light Chain Capturing Coupled with NanoRP-LC-MS

    by Yue Li, Sabrina Reusch, Bianca D. M. van Tol, Fiammetta Di Marco, Anna M. Wasynczuk, Steinar Gijze, David Falck, Manfred Wuhrer, Constantin Blöchl, Christoph Gstöttner, et al.

    The proteoform profile of antibody Fc domains determines antibody effector functions, not only for biopharmaceuticals but also for endogenous antibodies. Endogenous immunoglobulin G (IgG) Fc-proteoforms have been well characterized by using different MS-based approaches, comprising bottom-up and intact Fc domain workflows. However, assessment of IgA1 and IgM Fc domains is still challenging, due to the more complex structure, and analyses have been limited to the peptide level only. In this work, a light-chain affinity capturing workflow combined with isotype-specific hinge-region digestion and subsequent intact Fc domain nanoRP-LC-MS analysis has been developed. The novel approach shows very good sensitivity and precision, enabling simultaneous capturing of antibody isotypes with sequential release and analysis of IgG, IgA1 and IgM Fcs from 10 μL of plasma. Single donor human samples were successfully analyzed, providing a comprehensive overview on Fc proteoforms but also on associated Fc-components such as the joining (J) chain of IgA and IgM and CD5L.


  • Open Access

    GlycoDash: automated, visually assisted curation of glycoproteomics datasets for large sample numbers

    by Tamas Pongracz, Steinar Gijze, Agnes L. Hipgrave Ederveen, Rico J. E. Derks, David Falck

    The challenge of robust and automated glycopeptide quantitation from liquid chromatography-mass spectrometry (LC–MS) data has yet to be adequately addressed by commercial software. Recently, open-source tools like Skyline and LaCyTools have advanced the field of label-free MS1 level quantitation. Yet, important steps late in the data processing workflow remain manual. Because manual data curation is time-consuming and error-prone, it presents a bottleneck, especially in an era of emerging high-throughput methodologies and increasingly complex analyses such as antigen-specific antibody glycosylation. We addressed this gap by developing GlycoDash, an R Shiny-based interactive web application designed to democratize label-free high-throughput glycoproteomics data analysis. The software comes in at a stage where analytes have been identified and quantified, but whole measurement and individual analyte signals of insufficient quality for quantitation remain and reduce the quality of the overall dataset. GlycoDash focuses on these challenges by incorporating several options for measurement and metadata linking, spectral and analyte curation, normalization, and repeatability assessment, and additionally includes glycosylation trait calculation, data visualization, and reporting capabilities that adhere to FAIR principles. The performance and versatility of GlycoDash were demonstrated across antibody glycoproteomics data of increasing complexity, ranging from relatively simple monoclonal antibody glycosylation analysis to a clinical cohort with over a thousand measurements. In a matter of hours, these large, diverse, and complex datasets were curated and explored. High-quality datasets with integrated metadata ready for final analysis and visualization were obtained. Critical aspects of the curation strategy underlying GlycoDash are discussed. GlycoDash effectively automates and streamlines the curation of glycopeptide quantitation data, addressing a critical need for high-throughput glycoproteomics data analysis. Its robust performance across diverse datasets and its comprehensive feature toolbox significantly enhance both research and clinical applications in glycoproteomics. Graphical Abstract


  • Open Access

    Comprehensive Immunoglobulin G, A, and M Glycopeptide Profiling for Large-Scale Biomedical Research

    by Bianca D.M. van Tol, Anna M. Wasynczuk, Steinar Gijze, Oleg A. Mayboroda, Jan Nouta, Radboud J.E.M. Dolhain, Manfred Wuhrer, David Falck


  • Open Access

    Simultaneous Protein Quantitation and Glycosylation Profiling of Antigen-Specific Immunoglobulin G1 in Large Clinical Studies

    by Steinar Gijze, Anna Wasynczuk, Leanne van Leeuwen, Marloes Grobben, Marit J. van Gils, Jan Nouta, Wenjun Wang, Virgil Ash Dalm, Hetty Jolink, Manfred Wuhrer, et al.

    Antibodies have a key role in the immune system, making their characterization essential to biomedical, biopharmaceutical, and clinical research questions. Antibody effector functions are mainly controlled by quantity, subclass, and Fc glycosylation. We describe an integrated method to measure these three critical dimensions simultaneously. The subclass-specific immunoglobulin G (IgG) Fc glycosylation analysis combines immunosorbance with glycopeptide-centered LC-MS detection. For integrated IgG1-specific quantitation, a commercial, stable isotope labeled IgG1 protein standard was spiked into the immunosorbent eluates. Robust quantitation was achieved, relying on a combination of a proteotypic peptide and the most abundant glycopeptides, generated through proteolytic cleavage from a mixture of natural IgG1 and the recombinant IgG1 standard. Method performance was demonstrated in a large coronavirus vaccination cohort at a throughput of 100 samples/day. LC-MS-derived, anti-SARS-CoV-2 spike protein IgG1 concentrations ranged from 100 to 10000 ng/mL and correlated well with a clinically relevant immunoassay. Technical variation was 200 times lower than biological variation; intermediate precision was 44%. In conclusion, we present a method capable of robustly and simultaneously assessing quantity, subclass, and Fc glycosylation of antigen-specific IgG in large clinical studies. This method will facilitate a broader understanding of immune responses, especially the important interplay among the three dimensions.


  • Open Access

    Functional comparison of Fc-engineering strategies to improve anti-HIV-1 antibody effector functions

    by Angela I. Schriek, David Falck, Manfred Wuhrer, Neeltje A. Kootstra, Marit J. van Gils, Steven W. de Taeye


  • Open Access

    Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing

    by Steven W. de Taeye, Angela I. Schriek, Jeffrey C. Umotoy, Marloes Grobben, Judith A. Burger, Rogier W. Sanders, Gestur Vidarsson, Manfred Wuhrer, David Falck, Neeltje A. Kootstra, et al.

    Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have the capacity to delay viral rebound when administered to people with HIV-1 (PWH) during anti-retroviral therapy (ART) interruption. To further enhance the performance of bNAbs through their Fc effector functions, in particular NK cell-mediated killing of HIV-1 infected cells, we have produced a panel of glyco-engineered (afucosylated) bNAbs with enhanced affinity for Fc gamma receptor IIIa. These afucosylated anti-HIV-1 bNAbs enhance NK cell activation and degranulation compared to fucosylated counterparts even at low antigen density. NK cells from PWH expressing exhaustion markers PD-1 and TIGIT are activated in a similar fashion by afucosylated bNAbs as NK cell from HIV-1 negative individuals. Killing of HIV-1 infected cells is most effective with afucosylated bNAbs 2G12, N6, PGT151 and PGDM1400, whereas afucosylated PGT121 and non-neutralizing antibody A32 only induce minor NK cell-mediated killing. These data indicate that the approach angle and affinity of Abs influence the capacity to induce antibody-dependent cellular cytotoxicity. Thus, afucosylated bNAbs have the capacity to induce NK cell-mediated killing of infected cells, which warrants further investigation of afucosylated bNAb administration in vivo, aiming for reduction of the viral reservoir and ART free durable control.


  • GlYcoLISA: antigen-specific and subclass-specific IgG Fc glycosylation analysis based on an immunosorbent assay with an LC–MS readout

    by David Falck, Manfred Wuhrer

    Immunoglobulin G (IgG) fragment crystallizable (Fc) glycosylation modulates effector functions such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Consequently, assessing IgG Fc glycosylation is important for understanding the role of antibodies in infectious, alloimmune and autoimmune diseases. GlYcoLISA determines the Fc glycosylation of antigen-specific IgG by an immunosorbent assay with a liquid chromatography–mass spectrometry (LC–MS) readout. Detection of antigen-specific IgG glycosylation in a subclass- and site-specific manner is realized by LC–MS-based glycopeptide analysis after proteolytic cleavage. GlYcoLISA addresses challenges related to the low abundance of specific IgG and the high background of total IgG by using well-established immunosorbent assays for purifying antibodies of the desired specificity using immobilized antigen. Alternative methods with sufficient glycan resolution lack these important specificities. GlYcoLISA is performed in a 96-well plate format, and the analysis of 160 samples takes ~5 d, with 1 d for sample preparation, 2 d of LC–MS measurement and 2 d for partially automated data processing. GlYcoLISA requires expertise in LC–MS operation and data processing.


  • Open Access

    Erythropoietin N-glycosylation of Therapeutic Formulations Quantified and Characterized: An Interlab Comparability Study of High-Throughput Methods

    by Róisín O’flaherty, Manuela Amez Martín, Richard A. Gardner, Patrick M. Jennings, Pauline M. Rudd, Daniel I. R. Spencer, David Falck

    Recombinant human erythropoietin (EPO) is a biopharmaceutical frequently used in the treatment of anemia. It is a heavily glycosylated protein with a diverse and complex glycome. EPO N-glycosylation influences important pharmacological parameters, prominently serum half-life. Therefore, EPO N-glycosylation analysis is of the utmost importance in terms of controlling critical quality attributes. In this work, we performed an interlaboratory study of glycoanalytical techniques for profiling and in-depth characterization, namely (1) hydrophilic interaction liquid chromatography with fluorescence detection after 2-aminobenzamide labeling (HILIC-FLD(2AB)) and optional weak anion exchange chromatography (WAX) fractionation and exoglycosidase digestion, (2) HILIC-FLD after procainamide labeling (PROC) optionally coupled to electrospray ionization-MS and (3) matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-MS). All techniques showed good precision and were able to differentiate the unique N-glycosylation profiles of the various EPO preparations. HILIC-FLD showed higher precision, while MALDI-TOF-MS covered the most analytes. However, HILIC-FLD differentiated isomeric N-glycans, i.e., N-acetyllactosamine repeats and O-acetylation regioisomers. For routine profiling, HILIC-FLD methods are more accessible and cover isomerism in major structures, while MALDI-MS covers more minor analytes with an attractively high throughput. For in-depth characterization, MALDI-MS and HILIC-FLD(2AB)/WAX give a similar amount of orthogonal information. HILIC-FLD(PROC)-MS is attractive for covering isomerism of major structures with a significantly less extensive workflow compared to HILIC-FLD(2AB)/WAX.